Hepatitis B and C are among the most common viral infections in the world. At least 263 million worldwide in 2017 – are carriers of hepatitis B or C virus infections, which can remain asymptomatic for decades.1,2
95% of people living with viral
hepatitis do not know.
In 2016, the World Health Assembly adopted WHO’s first
“Global Health Sector Strategy on viral hepatitis,”
with elimination as its overarching vision.
Globally, 263 million
persons are infected
Vision, goal and targets
A world where viral hepatitis transmission is halted
and everyone living with viral hepatitis has access to
safe, affordable and effective prevention, care and
Eliminate viral hepatitis as a major public health
threat by 2030.
Between 6 and 10 million infections are
reduced to less than 1 million by 2030;
1.4 million deaths reduced to less than 500 000 by 2030.
A world where viral hepatitis transmission is halted and everyone living with viral hepatitis has access to safe, affordable and effective prevention, care and treatment services
Eliminate viral hepatitis as a major public health threat by 2030
72 countries projected to meet the 2030 target
of ≤0.1% HBsAg prevalence among 5-Year-Olds
Roche committed to the elimination of hepatitis
To advance global efforts and eliminate viral hepatitis, Roche is committed
to this motivational program underscoring our ongoing efforts to provide
life-saving diagnostics, and supports governments aiming to cure people
Roche is a leader in viral load testing and is dedicated to enabling
improved patient management by delivering innovative, high-quality
Some randomr randomr randomr randomr randomr randomr
To play the media you will need to either update your browser to a recent version or update your
Our policy on cookies and other tracking technologies